rs17147230 — IL6

Near-gene upstream variant in IL6 associated with hepatocellular carcinoma risk through altered interleukin-6 regulation — an independent inflammaging signal

See your personal result for IL6

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

IL-6 Upstream Variant rs17147230: An Independent Inflammaging Signal

Interleukin-6 (IL-6) is the master cytokine of inflammaging11 inflammaging
the chronic, low-grade sterile inflammation that accumulates with age and drives most age-related diseases, coined by Claudio Franceschi — the biological state where the immune system runs a persistent low-level inflammatory programme that damages tissues over decades. The rs17147230 variant sits approximately 3,300 base pairs upstream of the IL6 gene on chromosome 7, in a position that can influence how the gene is expressed. It represents an independent IL-6 genetic signal beyond the more-studied -174G/C variant (rs1800795), and its primary clinical evidence links elevated IL-6 output to hepatocellular carcinoma22 hepatocellular carcinoma
primary liver cancer arising from hepatocytes, one of the most prevalent cancers globally and strongly associated with chronic liver inflammation risk and altered inflammatory protein regulation.

The Mechanism

IL6 spans a tightly regulated promoter region with multiple transcription factor binding sites scattered across several kilobases upstream of the transcription start site. The rs17147230 variant at chr7:22,722,557 lies in this upstream regulatory zone. Though its precise molecular mechanism has not been characterised in the same detail as the -174G/C (rs1800795) promoter variant, its position within a region known to modulate IL-6 transcription suggests it can influence the amount of IL-6 produced in response to inflammatory stimuli such as viral infection, tissue damage, or metabolic stress.

IL-6 signals through two pathways: classic signalling33 classic signalling
IL-6 binds a membrane-bound IL-6 receptor (IL-6R) on cells that express it, mainly immune and liver cells — largely anti-inflammatory in context and trans-signalling44 trans-signalling
IL-6 binds a soluble form of IL-6R (sIL-6R) and signals to virtually all cell types — the mode most associated with chronic inflammation and disease. In the liver, chronically elevated IL-6 activates STAT355 STAT3
Signal Transducer and Activator of Transcription 3 — a transcription factor that, when persistently activated by IL-6, promotes cell survival, proliferation, and immune evasion in tumour cells, which drives hepatocyte proliferation and survival signalling that can tip chronically inflamed liver tissue toward malignancy.

The haplotype pairing of the rs17147230 T allele with the rs2069837 G allele produces a particularly potent HCC risk signal (OR 3.125 in the Wang et al. study), suggesting these two upstream variants co-operate to create an IL-6 expression profile that is especially conducive to chronic hepatic inflammation and carcinogenesis.

The Evidence

Hepatocellular carcinoma association: A case-control study by Wang et al.66 Wang et al.
Association of interleukin-6 polymorphisms with susceptibility to hepatocellular carcinoma. World J Gastroenterol, 2015 in 226 HCC cases and 220 healthy controls found the TT genotype carried a 2.1-fold increased HCC risk (OR=2.089, 95% CI 1.135–3.845, P=0.017) and the T allele carried a 1.3-fold increased risk (OR=1.326, 95% CI 1.010–1.740, P=0.042). The G-T haplotype combining rs2069837-G with rs17147230-T showed the strongest signal (OR=3.125, 95% CI 1.845–5.294, P<0.001).

Meta-analytic confirmation: A meta-analysis by He et al.77 meta-analysis by He et al.
Association between interleukin 6 polymorphisms and hepatocellular carcinoma susceptibility. J Clin Lab Anal, 2021 pooling 13 studies confirmed that the rs17147230 T allele (OR=1.31, P=0.03) and TT genotype (OR=1.83, P=0.02) were significantly associated with increased HCC susceptibility. This meta-analytic OR of 1.31–1.83 places rs17147230 in the moderate-risk category, consistent with a regulatory variant that modulates cancer risk rather than causing it directly.

Adrenomedullin regulation: A study by Lam et al.88 Lam et al.
A single nucleotide polymorphism of interleukin-6 gene is related to plasma adrenomedullin levels. Ann Med, 2013 found rs17147230 was associated with plasma adrenomedullin99 adrenomedullin
a vasodilatory peptide hormone with anti-inflammatory and cardioprotective properties (ADM) levels (β=−0.096, P=0.034) after adjusting for age and sex. Individuals with the TT genotype had approximately 12.8% lower ADM levels than AA homozygotes — a significant finding because lower ADM is associated with reduced vascular protection and higher inflammatory tone. The effect was significant in women (β=−0.115, P=0.021) but not men, suggesting sex-specific modulation.

Population context: The risk evidence for rs17147230 derives primarily from East Asian (Chinese) study populations, where the T allele has a frequency of approximately 34–41% — making it the minor allele in this ancestry group. Globally, T is the common allele (~81%), while in East Asian populations the allele frequency pattern inverts. This population stratification is clinically important: the HCC risk appears most pronounced in populations where T is the minority allele (East Asian), and may not translate uniformly to European populations.

Practical Implications

The core message of rs17147230 is about chronic liver inflammation management. The T allele, particularly in East Asian populations and in combination with the rs2069837-G haplotype, creates an IL-6 regulatory environment that can amplify hepatic inflammatory signalling over decades. Given that the transition from chronic liver inflammation → fibrosis → cirrhosis → HCC takes years to decades, this variant is most relevant as an early warning to be proactive about liver health behaviours.

The variant also connects to the broader inflammaging framework: IL-6 is one of the most important drivers of the chronic low-grade inflammatory state associated with accelerated biological aging. TT homozygotes — especially in East Asian populations where T is the minor allele — face the combination of elevated HCC risk and potentially accelerated inflammaging trajectories.

Because IL-6 regulation is influenced by diet, exercise, sleep, alcohol, and viral exposures (hepatitis B and C), there are concrete lifestyle levers available to individuals with this genotype.

Interactions

rs17147230 shows strong haplotypic interaction with rs2069837 (also in the IL6 upstream region): the G-T haplotype (rs2069837-G + rs17147230-T) triples HCC risk compared to the reference haplotype. Both variants lie upstream of IL6 and may co-operatively shape the IL-6 expression response to hepatic stress. The primary IL6 promoter variant rs1800795 (-174G/C) is an independent signal in strong linkage disequilibrium with rs1800797 but in weaker LD with rs17147230, providing an additive independent contribution to overall IL-6 regulation. For individuals carrying both TT at rs17147230 and GG at rs1800795, the combined inflammatory drive to the liver warrants heightened attention to hepatic health monitoring.

Genotype Interpretations

What each possible genotype means for this variant.

AA Typical IL-6 Upstream Normal

Standard IL-6 regulation upstream — no elevated HCC risk

You carry two copies of the A allele at this IL6 upstream regulatory variant. This is the common genotype in East Asian populations (approximately 40% in Chinese studies) and represents the lower-risk profile for hepatocellular carcinoma associated with this locus. Your IL-6 expression from this regulatory region is not elevated by the rs17147230 T allele, meaning this particular upstream signal does not contribute to heightened hepatic inflammatory tone or HCC susceptibility.

Note that globally, the A allele is actually the minor allele (approximately 19% frequency), so this genotype is uncommon outside East Asian populations.

AT One Risk Upstream Allele Intermediate

Carries one T allele — modestly elevated IL-6 inflammatory signalling

You carry one T allele and one A allele at this IL6 upstream variant. Heterozygous carriers have an intermediate IL-6 regulatory profile from this locus. In the primary HCC case-control studies (Chinese populations), the heterozygous genotype did not show statistically significant risk (OR=1.104, P=0.629), suggesting one T allele does not meaningfully increase HCC risk on its own.

The more important practical signal from this genotype is the association with adrenomedullin levels — heterozygotes may have moderately lower ADM levels than AA homozygotes, which connects to vascular inflammatory tone. Support liver health with alcohol limits and hepatitis B/C screening as standard care.

TT Homozygous Risk Upstream High Risk

Highest HCC-associated IL-6 upstream genotype — proactive liver monitoring warranted

The TT genotype creates the strongest IL-6 regulatory risk profile at this locus. The mechanism appears to involve the upstream regulatory region of IL6 influencing transcription factor accessibility or binding, though the precise molecular mechanism for rs17147230 has not been characterised at the biochemical level.

The haplotype evidence (G-T combining rs2069837 and rs17147230) is particularly compelling: OR=3.125 with 95% CI 1.845–5.294 (P<0.001) in the Wang et al. study. This suggests the two upstream variants co-operate to create a permissive chromatin environment for IL-6 transcription under hepatic stress.

Clinically, the connection between this variant and HCC runs through IL-6's role in liver cancer biology: IL-6 activates STAT3 in hepatocytes, which promotes survival, proliferation, and resistance to apoptosis. Chronically elevated IL-6 (as seen with hepatitis B or C infection, alcohol-related liver disease, or NAFLD) combined with a genetic predisposition for higher IL-6 output creates conditions for the decades-long inflammatory progression toward hepatocellular carcinoma.

The adrenomedullin association adds a cardiovascular/longevity dimension: lower ADM in TT carriers means reduced vasodilatory and anti-inflammatory protection, potentially contributing to accelerated vascular aging.